tiprankstipranks
Trending News
More News >
Lee's Pharmaceutical Holdings Limited (HK:0950)
:0950
Hong Kong Market
Advertisement

Lee's Pharmaceutical Holdings Limited (0950) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0950

Lee's Pharmaceutical Holdings Limited

(0950)

Rating:66Neutral
Price Target:
HK$2.00
▲(4.71% Upside)
The overall stock score of 66 reflects strong technical momentum and a stable valuation, offset by financial performance challenges, particularly in profitability and cash flow generation. The absence of earnings call insights and corporate events does not impact the score.

Lee's Pharmaceutical Holdings Limited (0950) vs. iShares MSCI Hong Kong ETF (EWH)

Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model

Company DescriptionLee's Pharmaceutical Holdings Limited is a pharmaceutical company based in China, specializing in the development, manufacture, and sale of proprietary pharmaceutical products. The company operates primarily in the cardiovascular, oncology, gynecology, dermatology, and ophthalmology sectors, offering a wide range of products to address various medical needs. Its core offerings include innovative drugs and medical devices aimed at improving health outcomes for patients across these therapeutic areas.
How the Company Makes MoneyLee's Pharmaceutical Holdings Limited generates revenue primarily through the sale of its proprietary pharmaceutical products in China and international markets. The company earns income by developing and commercializing drugs and medical devices, focusing on therapeutics for cardiovascular diseases, oncology, and other specialized fields. Key revenue streams include direct sales to hospitals, clinics, and healthcare providers, as well as through distribution partnerships and licensing agreements with other pharmaceutical companies. Strategic collaborations with international firms also play a significant role in enhancing its product portfolio and expanding its market reach, contributing to its overall earnings.

Lee's Pharmaceutical Holdings Limited Financial Statement Overview

Summary
Lee's Pharmaceutical Holdings Limited shows strong revenue growth and a stable balance sheet with low leverage. However, challenges exist in profitability with a low net profit margin and concerning cash flow generation.
Income Statement
60
Neutral
The company shows a stable gross profit margin of 53.8% in 2024, indicating efficient production processes. However, the net profit margin is relatively low at 6.6%, suggesting high expenses or cost pressures. Revenue growth was 32.9% from 2023 to 2024, a strong recovery from previous periods, but historically, revenue has been inconsistent, highlighting potential market challenges.
Balance Sheet
70
Positive
The balance sheet reflects a solid equity position with an equity ratio of 63.1%, showing financial stability. The debt-to-equity ratio is low at 0.14, indicating prudent leverage levels. However, the return on equity (ROE) is modest at 5.6%, suggesting room for improved profitability.
Cash Flow
50
Neutral
Cash flow performance is concerning with zero operating and free cash flow in 2024, indicating potential liquidity issues. The free cash flow growth rate is unavailable due to missing data, and the operating cash flow to net income ratio cannot be determined, pointing to challenges in cash generation.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.40B1.05B1.23B1.27B1.22B
Gross Profit753.36M551.31M770.75M806.28M781.07M
EBITDA260.87M193.05M229.06M2.13B279.43M
Net Income93.10M16.70M51.28M1.99B78.53M
Balance Sheet
Total Assets2.62B2.89B2.78B3.64B3.25B
Cash, Cash Equivalents and Short-Term Investments216.84M171.00M189.30M277.53M414.54M
Total Debt227.30M204.14M163.49M267.14M156.71M
Total Liabilities1.07B930.07M939.50M1.25B1.14B
Stockholders Equity1.65B2.04B1.92B2.46B2.15B
Cash Flow
Free Cash Flow34.45M-45.89M69.81M-160.04M-139.23M
Operating Cash Flow242.01M110.08M283.63M210.68M218.91M
Investing Cash Flow-192.36M-145.22M-256.05M-370.28M-523.74M
Financing Cash Flow-1.96M13.44M-128.60M60.97M-9.80M

Lee's Pharmaceutical Holdings Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.91
Price Trends
50DMA
1.63
Positive
100DMA
1.49
Positive
200DMA
1.38
Positive
Market Momentum
MACD
0.12
Negative
RSI
53.19
Neutral
STOCH
49.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Neutral. The current price of 1.91 is above the 20-day moving average (MA) of 1.85, above the 50-day MA of 1.63, and above the 200-day MA of 1.38, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 53.19 is Neutral, neither overbought nor oversold. The STOCH value of 49.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0950.

Lee's Pharmaceutical Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$6.43B7.0611.61%6.07%-18.09%-15.08%
73
Outperform
HK$1.97B3.2218.33%5.78%-9.95%67.56%
70
Outperform
HK$10.52B11.608.89%3.81%4.91%-11.80%
66
Neutral
HK$1.12B12.085.04%2.39%32.95%456.69%
60
Neutral
HK$19.22B4.48-1.43%3.30%11.19%-15.58%
49
Neutral
$13.90B-4.93%1.41%-0.11%-290.77%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0950
Lee's Pharmaceutical Holdings Limited
1.85
0.66
55.46%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
7.89
2.86
56.86%
HK:2877
China Shineway Pharmaceutical Group Limited
8.32
0.77
10.20%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.29
0.27
26.47%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.44
0.93
182.35%

Lee's Pharmaceutical Holdings Limited Corporate Events

Lee’s Pharmaceutical Announces Board Meeting to Review Interim Results
Aug 14, 2025

Lee’s Pharmaceutical Holdings Limited has announced a board meeting scheduled for August 26, 2025, to discuss and approve the unaudited interim results for the first half of 2025, and to consider the recommendation of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.

Lee’s Pharmaceutical Gains Approval for New Oncology Drug in China
Jul 31, 2025

Lee’s Pharmaceutical Holdings Limited announced the approval of Socazolimab, an oncology drug developed by its subsidiary China Oncology Focus Limited, for marketing in combination with chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer in Mainland China. The approval by the National Medical Products Administration is based on a successful Phase III clinical trial that demonstrated significant overall survival benefits without increasing safety risks. This development strengthens Lee’s Pharm’s position in the oncology market and underscores its commitment to advancing cancer treatment options.

Lee’s Pharmaceutical Successfully Passes All AGM Resolutions
May 22, 2025

Lee’s Pharmaceutical Holdings Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. Key resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 12, 2025